ReviewStem cell research & therapy2025
Next-generation osteoarthritis models: integrating biological, computational, and engineering approaches.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanomaterials targeting ferroptosis for osteoarthritis treatment: a systematic review of preclinical evidence.Journal of nanobiotechnology · 2026Pooled it
- From molecular networks to the clinic: a systems biology-nanomedicine roadmap for osteoarthritis diagnosis, regeneration, and safety-by-design.Discover nano · 2026Review
- Mesenchymal stromal cells therapy for remodeling the joint microenvironment: mechanisms, nanotechnology-enhanced strategies, and translation prospects.Stem cell research & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Osteoarthritis (OA) is a complex degenerative joint disease with substantial global health implications, yet effective disease-modifying treatments remain elusive. This review explores next-generation models revolutionizing OA research, including microfluidic organ-on-a-chip (OOAC) platforms, organoid systems, computational modelling, finite element analysis (FEA), and artificial intelligence (AI). OOAC systems replicate joint microenvironments, integrating biomechanical stimulation and dynamic tissue interactions, thereby enabling precise investigations of inflammatory and degenerative processes. While organoid technologies capture cellular heterogeneity and self-organization, they primarily serve as static, multicellular models rather than dynamic biomechanical systems. FEA provides high-resolution, patient-specific simulations of joint mechanics and cartilage degeneration, offering insights into mechanical stress distribution and OA progression. Computational modelling and AI enhance predictive capabilities, facilitating precision medicine approaches and optimizing treatment strategies. Despite significant advancements, critical challenges remain, particularly regarding biological fidelity, cross-model integration, and clinical translation. Ensuring computer-based model validation against curated, high-quality datasets-including patient-derived biomechanical, imaging, and molecular data-is imperative for increasing accuracy and translatability. By improving early diagnosis, treatment personalization, and cost-effective therapeutic screening, these advanced technologies can inform healthcare policies, optimize resource allocation, and shape evidence-based guidelines for OA management. This review underscores the necessity of interdisciplinary collaboration to refine these advanced platforms, bridge the gap between preclinical and clinical research, and accelerate the development of patient-specific OA interventions while informing adequate healthcare policies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.